The Breast: August 2019
Volume 46, Pages 19–24
by S.P. Corona, G. Roviello, C. Strina, M. Milani, S.
Madaro, D. Zanoni, G. Allevi, S. Aguggini, M.R. Cappelletti, M. Francaviglia,
C. Azzini, A. Cocconi, M. Sirico, M. Bortul, F. Zanconati, F. Giudici, P.
Rosellini, F. Meani, O. Pagani, D. Generali
Endocrine treatment with Tamoxifen and aromatase inhibitors
(AIs) is a staple in the management of hormone receptor positive breast cancer
(HR + BC). It has become clear that HR + BC carries a
consistent risk of relapse up to 15 years post-diagnosis. While increasing
evidence supports the use of extended adjuvant Tamoxifen over 5 years,
controversial data are available on the optimal duration of extended AIs
adjuvant treatment.We performed a meta-analysis to assess the real impact of
extended adjuvant therapy with AIs on disease-free survival (DFS).
